Identity
Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), also called LHRH — the natural decapeptide released by the hypothalamus that controls the entire reproductive hormone cascade. It is the same molecule the body makes; "gonadorelin" is simply its name as a manufactured drug.
Mechanism (as proposed / established)
GnRH sits at the top of the hypothalamic-pituitary-gonadal (HPG) axis. Released in pulses, it drives the pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drive the gonads to produce testosterone or estrogen and support gametogenesis. The single most important fact about it is the pulsatile-versus-continuous distinction: given in pulses it stimulates the axis; given continuously it paradoxically shuts it down — receptor desensitisation that is the deliberate basis of GnRH-agonist therapies in prostate cancer and endometriosis. This is textbook, well-established endocrinology.
The approved reality, and the research-channel gap
As a medicine, gonadorelin has defined diagnostic uses (probing pituitary function) and therapeutic uses (pulsatile delivery in specific hypothalamic infertility). Those uses are real and approved. But they are delivered a specific way — pulsatile, supervised, for defined indications — and the molecule has a very short half-life. The research-channel framing ("inject to raise testosterone or support fertility") borrows the endocrinology while dropping the method that makes it work, and casual or continuous dosing can suppress the very axis it is meant to stimulate. The approved standing is genuine; it does not transfer to unsupervised use.